Sponsor Check › Issuer
Corporation · organized in DELAWARE · formed more than five years before filing · TUCSON, AZ · SEC CIK 727207 · formerly ACCELR8 TECHNOLOGY CORP; HYDRO SEEK INC
Data last updated: Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer: Apr 7, 2022 · Courts (RECAP) last checked: Oct 23, 2026, 11:54 PM ET · SEC enforcement last checked: not yet
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
1 case: 1 judgment
850 Other Statutes: Securities/Commodities· Cause:
15:78m(a) Securities Exchange Act
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:54 PM ET. Court records show docket facts only; we never restate allegations as facts. Outcome wording comes from the docket feed; where it does not state a disposition we say so.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:54 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
No public statement by this issuer has been collected yet, so there is nothing to compare. Sources compared: the sponsor's own website (known only from an approved profile claim or the Form ADV of its matched adviser) · SEC Form D · SEC Form ADV (IAPD) · Internet Archive · No website is on file for this issuer yet.
1 of 8 offerings reports sales commissions totalling $15,000; 0 report finder's fees; 0 report proceeds to related persons.
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Apr 7, 2022 D File 021-440898 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 29, 2021 D/A File 021-390838 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 29, 2021 D File 021-414960 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 28, 2019 D File 021-347568 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 4, 2014 D File 021-218526 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 26, 2013 D File 021-201867 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 17, 2012 D File 021-181344 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Mar 23, 2010 D File 021-72720-7D | $15,000 | $0 | $0 Proceeds will be used for various working capital purposes, which may include payment of salaries to officers. | Brad A. Parobek no CRD number reported via Janco Partners (CRD 4055 ↗) |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
0 recorded documents and 0 ownership records matched to Accelerate Diagnostics, Inc in the sources searched.
Not found in sources searched as of Oct 23, 2026, 8:59 PM ET: Hillsborough County FL Clerk of Court Official Records daily index (publicrec.hillsclerk.com D/P/M files), 2 daily files (Oct 14, 2026 to Oct 15, 2026) — loaded Oct 23, 2026, 8:59 PM ET; Florida DOR NAL roll (Hillsborough 39) roll year 2026 — loaded Oct 23, 2026, 8:54 PM ET; Florida DOR NAL roll (Dade 23) roll year 2026 — loaded Oct 23, 2026, 8:58 PM ET; Harris County Appraisal District real_acct.txt roll year 2026 — loaded Oct 23, 2026, 8:58 PM ET; Dallas Central Appraisal District ACCOUNT_INFO.CSV roll year 2026 — loaded Oct 23, 2026, 8:58 PM ET. Not yet searched for this issuer (queued): NYC ACRIS via NYC Open Data (Real Property Parties 636b-3b5g, Master bnx9-e6tj, Legals 8h5j-fqxa, Document Control Codes 7isb-wh4c) · NYC PLUTO ownership via NYC Open Data (64uk-42ks) · Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp). Records in other counties, and recorder indexes we do not yet cover, were not searched.
Property records coverage: New York City (ACRIS recorded documents and PLUTO ownership, looked up per issuer when its page is viewed; re-checked when the page is viewed again more than 30 days after the last check); Hillsborough County FL (recorded documents from Oct 14, 2026 forward; ownership from FL DOR roll 2026); Cook County IL (assessor ownership and deed/sale records, looked up per issuer when its page is viewed); Harris County TX and Dallas County TX (assessor ownership rolls only, 2026 roll; no deed, mortgage or sale records); Miami-Dade County FL (ownership from FL DOR roll only; Clerk recorded documents not yet searched). Recorder indexes for TX, AZ, IL and WA counties, mortgages and liens outside NYC and FL, lis pendens and foreclosure notices everywhere, Miami-Dade County FL recorded documents, Maricopa County AZ, King County WA, Salt Lake County UT, and all other counties are not yet searched. Last refresh: Oct 23, 2026, 11:30 PM ET; last subject check: Oct 24, 2026, 12:00 AM ET. Parties are named as the recorder's index names them (role suffixes as recorded); no address is shown for an individual, and individual owners of record (home ownership) are not matched or shown. Items still in human review are not shown.
Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.
| File no. | Original Form D | Latest filing | Amendments | Offered (latest) | Sold (latest) | Industry (latest) |
|---|---|---|---|---|---|---|
| 021-440898 | Apr 7, 2022 EDGAR ↗ | Apr 7, 2022 D EDGAR ↗ | 0 | $4,000,000 | $4,000,000 | Biotechnology |
| 021-414960 | Sep 29, 2021 EDGAR ↗ | Sep 29, 2021 D EDGAR ↗ | 0 | $30,450,000 | $30,450,000 | Biotechnology |
| 021-390838 | Mar 1, 2021 EDGAR ↗ | Sep 29, 2021 D/A EDGAR ↗ | 1 latest Sep 29, 2021 | $1,550,000 | $1,550,000 | Biotechnology |
| 021-347568 | Aug 28, 2019 EDGAR ↗ | Aug 28, 2019 D EDGAR ↗ | 0 | $999,992 | $999,992 | Biotechnology |
| 021-218526 | Jun 4, 2014 EDGAR ↗ | Jun 4, 2014 D EDGAR ↗ | 0 | $19,499,609 | $19,499,609 | Biotechnology |
| 021-201867 | Aug 26, 2013 EDGAR ↗ | Aug 26, 2013 D EDGAR ↗ | 0 | Indefinite | $3,321,244 | Biotechnology |
| 021-181344 | Jul 17, 2012 EDGAR ↗ | Jul 17, 2012 D EDGAR ↗ | 0 | $14,420,000 | $14,420,000 | Biotechnology |
| 021-72720-7D | Mar 23, 2010 EDGAR ↗ | Mar 23, 2010 D EDGAR ↗ | 0 | $2,000,000 | $275,000 | Other Health Care |
Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.
| Filing | Form D filed Apr 7, 2022 SEC file no. 021-440898 · accession 0001104659-22-043623 |
|---|---|
| Raise progress | $4,000,000 sold of $4,000,000 offered (100%) · $0 remaining · first sale Mar 24, 2022 |
| Filing timing | Date of first sale: Mar 24, 2022 · Form D filed: Apr 7, 2022 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 1,675 days (4.6 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 3 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: $5,000,001 - $25,000,000 (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Steve Reichling, Chief Financial Officer (Apr 7, 2022) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $4,000,000. Typical range: $2,000,000–$19,999,994. Investors: 3. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Sep 29, 2021 SEC file no. 021-414960 · accession 0001104659-21-120361 |
|---|---|
| Raise progress | $30,450,000 sold of $30,450,000 offered (100%) · $0 remaining · first sale Sep 22, 2021 |
| Filing timing | Date of first sale: Sep 22, 2021 · Form D filed: Sep 29, 2021 (7 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 1,858 days (5.1 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 3 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: $5,000,001 - $25,000,000 (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Steve Reichling, Chief Financial Officer (Sep 28, 2021) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $30,450,000. Typical range: $2,000,000–$19,999,994. Investors: 3. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D/A (amendment) filed Sep 29, 2021 · amends 0001104659-21-029937 ↗ SEC file no. 021-390838 · accession 0001104659-21-120360 · filing 2 of 2 in this offering |
|---|---|
| Raise progress | $1,550,000 sold of $1,550,000 offered (100%) · $0 remaining · first sale Dec 24, 2020 |
| Filing timing | Date of first sale: Dec 24, 2020 · Original Form D filed: Mar 1, 2021 (67 days after first sale) · This amendment (Form D/A) filed: Sep 29, 2021 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
| Time since first sale | 2,130 days (5.8 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Sep 29, 2021. Most recent amendment for this offering in our index: this filing, Sep 29, 2021. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 5 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: $5,000,001 - $25,000,000 (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Steve Reichling, Chief Financial Officer (Sep 28, 2021) |
| Changes vs previous filing |
Compared with the D filed Mar 1, 2021 (EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $1,550,000. Typical range: $2,000,000–$19,999,994. Investors: 5. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Mar 1, 2021 SEC file no. 021-390838 · accession 0001104659-21-029937 · filing 1 of 2 in this offering |
|---|---|
| Raise progress | $32,000,000 sold of $32,000,000 offered (100%) · $0 remaining · first sale Dec 24, 2020 |
| Filing timing | Date of first sale: Dec 24, 2020 · Form D filed: Mar 1, 2021 (67 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 2,130 days (5.8 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Sep 29, 2021 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 8 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: $5,000,001 - $25,000,000 (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Steve Reichling, Chief Financial Officer (Mar 1, 2021) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $32,000,000. Typical range: $2,000,000–$19,999,994. Investors: 8. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Aug 28, 2019 SEC file no. 021-347568 · accession 0001144204-19-042070 |
|---|---|
| Raise progress | $999,992 sold of $999,992 offered (100%) · $0 remaining · first sale Aug 20, 2019 |
| Filing timing | Date of first sale: Aug 20, 2019 · Form D filed: Aug 28, 2019 (8 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 2,622 days (7.2 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Steve Reichling, Chief Financial Officer (Aug 28, 2019) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $999,992. Typical range: $2,000,000–$19,999,994. Investors: 1. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Jun 4, 2014 SEC file no. 021-218526 · accession 0001144204-14-035544 |
|---|---|
| Raise progress | $19,499,609 sold of $19,499,609 offered (100%) · $0 remaining · first sale May 19, 2014 |
| Filing timing | Date of first sale: May 19, 2014 · Form D filed: Jun 4, 2014 (16 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 4,541 days (12.4 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 4 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Steve Reichling, Chief Financial Officer (Jun 3, 2014) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $19,499,609. Typical range: $2,000,000–$19,999,994. Investors: 4. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Aug 26, 2013 SEC file no. 021-201867 · accession 0001144204-13-047808 |
|---|---|
| Raise progress | $3,321,244 sold of Indefinite offered · Indefinite remaining · first sale Aug 14, 2013 |
| Filing timing | Date of first sale: Aug 14, 2013 · Form D filed: Aug 26, 2013 (12 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 4,819 days (13.2 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: $1 - $1,000,000 (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | STEVE REICHLING, CHIEF FINANCIAL OFFICER (Aug 26, 2013) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: Indefinite. Typical range: $2,000,000–$19,999,994. Investors: 1. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Jul 17, 2012 SEC file no. 021-181344 · accession 0001144204-12-039720 |
|---|---|
| Raise progress | $14,420,000 sold of $14,420,000 offered (100%) · $0 remaining · first sale Jun 26, 2012 |
| Filing timing | Date of first sale: Jun 26, 2012 · Form D filed: Jul 17, 2012 (21 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 5,233 days (14.3 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: $1,000,001 - $5,000,000 (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Lawrence Mehren, Chief Executive Officer (Jul 16, 2012) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $14,420,000. Typical range: $2,000,000–$19,999,994. Investors: 1. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Mar 23, 2010 SEC file no. 021-72720-7D · accession 0001000096-10-000040 |
|---|---|
| Raise progress | $275,000 sold of $2,000,000 offered (14%) · $1,725,000 remaining · first sale Mar 17, 2010 |
| Filing timing | Date of first sale: Mar 17, 2010 · Form D filed: Mar 23, 2010 (6 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 6,065 days (16.6 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 7 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
| Minimum investment accepted | $25,000 |
| Securities offered | Equity; Option, warrant or other right to acquire |
| Entity details | Organized in DELAWARE · formed more than five years before filing · revenue range: $1 - $1,000,000 (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Other Health Care |
| Who is paid to sell it | Brad A. Parobek — no CRD number reported · associated broker-dealer: Janco Partners (CRD 4055 ↗) |
| Money to insiders | Sales commissions: $15,000 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 Issuer's note: Proceeds will be used for various working capital purposes, which may include payment of salaries to officers. |
| Signed by | Thomas V. Geimer, Chief Executive Officer (Mar 17, 2010) |
| Market context | Minimum investment: $25,000. Typical range for similar offerings: $10,000–$54,310. Offering size: $2,000,000. Typical range: $829,831–$9,999,998. Investors: 7. Typical range: 2–15. "Similar" = Other Health Care, Rule 506(b). Based on 4,189 Form D filings 2021–2026 in the same industry and exemption (Other Health Care, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 1,330, offering size 3,970, investors 3,669. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Amendment filed | File no. | Compared with | What changed (both values as filed) |
|---|---|---|---|
| Sep 29, 2021 EDGAR ↗ | 021-390838 | Mar 1, 2021 D | total sold: $32,000,000 (Mar 1, 2021) → $1,550,000 (Sep 29, 2021) · total offering: $32,000,000 (Mar 1, 2021) → $1,550,000 (Sep 29, 2021) · investors: 8 (Mar 1, 2021) → 5 (Sep 29, 2021) · and 2 more (open the filing above) |
Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Values as filed; no conclusion is drawn.
All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Apr 7, 2022. Industry as reported, by offering: Previous offerings: Other Health Care (2010). Latest offering: Biotechnology (2012–2022; most recent Apr 7, 2022).
| Name | Relationship | Address state | On filings (first → last) | Also listed on |
|---|---|---|---|---|
| Charles Watts | Director | AZ | Aug 28, 2019 → Apr 7, 2022 on 5 of 9 filings listed on the latest filing | 1 other issuer |
| Frank J.M. ten Brink also filed as FRANK J.M. ten BRINK | Director | AZ | Aug 26, 2013 → Apr 7, 2022 on 7 of 9 filings listed on the latest filing | — |
| Hany Massarany | Director | AZ | Sep 29, 2021 → Apr 7, 2022 on 3 of 9 filings listed on the latest filing | 1 other issuer |
| Jack Schuler also filed as JACK SCHULER | Director | CO | Jul 17, 2012 → Apr 7, 2022 on 8 of 9 filings listed on the latest filing | 12 other issuers |
| John J. Phillips | Executive Officer, Director | AZ | Aug 28, 2019 → Apr 7, 2022 on 5 of 9 filings listed on the latest filing | — |
| John Patience also filed as JOHN PATIENCE | Director | CO | Jul 17, 2012 → Apr 7, 2022 on 8 of 9 filings listed on the latest filing | 1 other issuer |
| Louise L. Francesconi | Director | AZ | Mar 1, 2021 → Apr 7, 2022 on 4 of 9 filings listed on the latest filing | — |
| Mark Miller also filed as Mark C. Miller | Director | AZ | Jun 4, 2014 → Apr 7, 2022 on 6 of 9 filings listed on the latest filing | 1 other issuer |
| Matthew Strobeck also filed as Matthew W. Strobeck | Director | CO | Jul 17, 2012 → Apr 7, 2022 on 6 of 9 filings listed on the latest filing | 6 other issuers |
| Ron Price | Executive Officer, Director | AZ | Aug 28, 2019 → Apr 7, 2022 on 5 of 9 filings listed on the latest filing | — |
| Steve Reichling also filed as STEVE REICHLING | Executive Officer | AZ | Aug 26, 2013 → Apr 7, 2022 on 7 of 9 filings listed on the latest filing | — |
| Thomas D. Brown | Director | AZ | Aug 28, 2019 → Apr 7, 2022 on 5 of 9 filings listed on the latest filing | — |
| Wayne C. Burris | Director | AZ | Apr 7, 2022 on 1 of 9 filings listed on the latest filing | — |
| Roland Diggelmann | Director | AZ | Mar 1, 2021 on 1 of 9 filings not listed on the latest filing (Apr 7, 2022) | — |
| Lawrence Mehren also filed as LAWRENCE MEHREN | Executive Officer, Director | CO | Jul 17, 2012 → Aug 28, 2019 on 4 of 9 filings not listed on the latest filing (Apr 7, 2022) | 1 other issuer |
| Romney Humphries | Executive Officer | AZ | Aug 28, 2019 on 1 of 9 filings not listed on the latest filing (Apr 7, 2022) | — |
| Matthew W. Strobeck, Ph.D also filed as Matthew W. Strobeck; Ph.D | Director | AZ | Jun 4, 2014 on 1 of 9 filings not listed on the latest filing (Apr 7, 2022) | — |
| Pete Bantock | Executive Officer | AZ | Jun 4, 2014 on 1 of 9 filings not listed on the latest filing (Apr 7, 2022) | — |
| MATHEW W STROBECK | Director | AZ | Aug 26, 2013 on 1 of 9 filings not listed on the latest filing (Apr 7, 2022) | — |
| Thomas V. Geimer also filed as Thomas Geimer | Director, Executive Officer | CO | Mar 23, 2010 → Jul 17, 2012 on 2 of 9 filings not listed on the latest filing (Apr 7, 2022) | — |
| Charles E. Gerretson | Director | CO | Mar 23, 2010 on 1 of 9 filings not listed on the latest filing (Apr 7, 2022) | — |
| David C. Howson | Executive Officer | CO | Mar 23, 2010 on 1 of 9 filings not listed on the latest filing (Apr 7, 2022) | — |
| John D. Kucera | Director | CO | Mar 23, 2010 on 1 of 9 filings not listed on the latest filing (Apr 7, 2022) | — |
Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings with the same first and last name and no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗. Middle names: the SEC Form D data set (RELATEDPERSONS.tsv) repeats the previous person's middle name into later rows of the same filing; where that happened PartnerFacts shows the name without the repeated middle name and keeps the data-set spelling on record (Charles J.M. Watts; Hany J.M. Massarany; Jack C. Schuler; John C. Patience; Ron J.M. Price; Steve J.M. Reichling; Roland J.M. Diggelmann; Lawrence D. Mehren; Romney J.M. Humphries; Pete J.M. Bantock) — the filing on EDGAR is the source.
Other issuers listing the same people:
Shared address: this business address appears on no other issuer's filings in our index. As of Oct 23, 2026, 5:45 PM ET.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Not yet searched. Sources to be searched: SEC Investment Adviser Information Reports — Form ADV data for SEC-registered advisers and exempt reporting advisers (file dated 2026-10-02); SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.
Not yet searched.
Sources to be searched: the sponsor's own website (known only from an approved profile claim or the matched adviser's Form ADV) for Meta Pixel ids and Facebook / Instagram page links; Meta Ad Library API: not yet searched (API access pending). We never read facebook.com or instagram.com; readers get a link to Meta's public Ad Library instead.
Not yet collected.
Sources to be searched: sponsor website, Internet Archive, press index (GDELT), Form ADV. A sponsor's website is known only from an approved profile claim or the Form ADV of its matched adviser (Item 1.I); we never look it up elsewhere and never collect personal or family accounts.
Entity standing: not checked (no official programmatic source for AZ yet).
Export this report as PDF (all source links + data timestamp; members · included free during the launch period) · Premium
Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".
No corrections have been requested for this page.
Filing-to-filing changes are in Amendment history above.
The complete public-record profile for Accelerate Diagnostics, Inc, plus the weekly new-filings list.
Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.
Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).
Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.
Free. Get the "Claimed by sponsor" chip and a confirmed contact for corrections. Claiming never changes the public-record section.